Comparison of clinicopathological features and treatment outcomes for cutaneous melanomas of the head and neck and melanomas arising at other sites: Implications for systemic therapy.

Autor: Li AT; Melanoma Institute Australia, The University of Sydney, North Sydney, NSW, Australia; Royal Prince Alfred Hospital, Camperdown, NSW, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia; Victorian Melanoma Service, The Alfred Hospital, Melbourne, VIC, Australia., Xu JX; Melanoma Institute Australia, The University of Sydney, North Sydney, NSW, Australia; Royal Prince Alfred Hospital, Camperdown, NSW, Australia., Blah TR; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia., Lo SN; Melanoma Institute Australia, The University of Sydney, North Sydney, NSW, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia., Saw RP; Melanoma Institute Australia, The University of Sydney, North Sydney, NSW, Australia; Royal Prince Alfred Hospital, Camperdown, NSW, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia; Mater Hospital, Sydney, NSW, Australia., Varey AH; Melanoma Institute Australia, The University of Sydney, North Sydney, NSW, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia; Westmead and Blacktown Hospitals, Sydney, NSW, Australia., Van Akkooi A; Melanoma Institute Australia, The University of Sydney, North Sydney, NSW, Australia; Royal Prince Alfred Hospital, Camperdown, NSW, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia; Mater Hospital, Sydney, NSW, Australia., Carlino MS; Melanoma Institute Australia, The University of Sydney, North Sydney, NSW, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia; Westmead and Blacktown Hospitals, Sydney, NSW, Australia., Pires da Silva I; Melanoma Institute Australia, The University of Sydney, North Sydney, NSW, Australia; Mater Hospital, Sydney, NSW, Australia; Westmead and Blacktown Hospitals, Sydney, NSW, Australia; Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia., Menzies AM; Melanoma Institute Australia, The University of Sydney, North Sydney, NSW, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia; Mater Hospital, Sydney, NSW, Australia; Royal North Shore Hospital, St Leonards, NSW, Australia., Shannon KF; Melanoma Institute Australia, The University of Sydney, North Sydney, NSW, Australia; Royal Prince Alfred Hospital, Camperdown, NSW, Australia; Mater Hospital, Sydney, NSW, Australia., Long GV; Melanoma Institute Australia, The University of Sydney, North Sydney, NSW, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia; Mater Hospital, Sydney, NSW, Australia; Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia; Royal North Shore Hospital, St Leonards, NSW, Australia., Scolyer RA; Melanoma Institute Australia, The University of Sydney, North Sydney, NSW, Australia; Royal Prince Alfred Hospital, Camperdown, NSW, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia; Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia; NSW Health Pathology, Sydney, NSW, Australia., Thompson JF; Melanoma Institute Australia, The University of Sydney, North Sydney, NSW, Australia; Royal Prince Alfred Hospital, Camperdown, NSW, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia; Mater Hospital, Sydney, NSW, Australia; Faculty of Health and Medical Sciences, The University of Western Australia, Perth, WA, Australia., Ch'ng S; Melanoma Institute Australia, The University of Sydney, North Sydney, NSW, Australia; Royal Prince Alfred Hospital, Camperdown, NSW, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia; Mater Hospital, Sydney, NSW, Australia; Chris O'Brien Lifehouse Cancer Centre, Camperdown, NSW, Australia. Electronic address: sydney.chng@sydney.edu.au.

Publikováno v: Journal of the American Academy of Dermatology [J Am Acad Dermatol] 2024 Sep 06. Date of Electronic Publication: 2024 Sep 06.

Development and validation of risk calculators for people with "thin" melanomas on their skin to predict the likelihood that their cancer will return: a plain language summary of publication.

Autor: Sharouni ME; Department of Dermatology, University Medic al Center Utrecht, Utrecht University, Utrecht, the Netherlands.; Melanoma Institute Australia, The University of Sydney, North Sydney, NSW, Australia., Lo SN; Melanoma Institute Australia, The University of Sydney, North Sydney, NSW, Australia.; Faculty of Medicine & Health, The University of Sydney, Sydney, NSW, Australia., Varey AH; Department of Dermatology, University Medic al Center Utrecht, Utrecht University, Utrecht, the Netherlands.; Faculty of Medicine & Health, The University of Sydney, Sydney, NSW, Australia.; Department of Plastic & Reconstructive Surgery, Westmead Hospital, Sydney, NSW, Australia., Elias SG; Julius Center for Health Sciences & Primary Care, University Medical Center Utrecht, University Utrecht, Utrecht, the Netherlands., Witkamp AJ; Department of Surgery, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands., Sigurdsson V; Department of Dermatology, University Medic al Center Utrecht, Utrecht University, Utrecht, the Netherlands., Suijkerbuijk KP; Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands., van Diest PJ; Department of Pathology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands., van Gils CH; Julius Center for Health Sciences & Primary Care, University Medical Center Utrecht, University Utrecht, Utrecht, the Netherlands., Blokx WA; Department of Pathology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands., Scolyer RA; Melanoma Institute Australia, The University of Sydney, North Sydney, NSW, Australia.; Faculty of Medicine & Health, The University of Sydney, Sydney, NSW, Australia.; Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia., Thompson JF; Melanoma Institute Australia, The University of Sydney, North Sydney, NSW, Australia.; Faculty of Medicine & Health, The University of Sydney, Sydney, NSW, Australia.; Department of Melanoma & Surgical Oncology, Royal Prince Alfred Hospital, Sydney, NSW, Australia.

Publikováno v: Future oncology (London, England) [Future Oncol] 2023 Jan; Vol. 19 (2), pp. 97-102. Date of Electronic Publication: 2023 Feb 10.

Australian general practitioners' attitudes and knowledge of sentinel lymph node biopsy in melanoma management.

Autor: Watts CG; MPH, PhD, Research Fellow, Cancer Epidemiology and Prevention Research, Sydney School of Public Health, The University of Sydney, NSW; Research Fellow, Surveillance, Evaluation and Research Program, Kirby Institute, UNSW, NSW., Smith AL; MPH, PhD, Research Fellow, Centre for Healthcare Resilience and Implementation Science (CHRIS), Australian Institute of Health Innovation (AIHI), Faculty of Medicine and Health Sciences, Macquarie University, NSW., Robinson S; BAppPH, Research Officer, Cancer Epidemiology and Prevention Research, Sydney School of Public Health, University of Sydney, NSW., Chang CS; MD, Research Assistant, Cancer Epidemiology and Prevention Research, Sydney School of Public Health, University of Sydney, NSW., Goumas C; MPH, Biostatistician, Cancer Epidemiology and Prevention Research, Sydney School of Public Health, University of Sydney, NSW., Schmid H; MPH, Co-ordinator, Melanoma Research Program, Westmead institute for Medical Research, NSW., Kelly JW; MD, Adjunct Professor, Monash University Department of Medicine at Alfred Health, Consultant Dermatologist, Victorian Melanoma Service, Melbourne, Vic., Hong AM; MBBS, MMed, PhD, FRANZCR, Radiation Oncologist, Melanoma Institute Australia, Chris O'Brien Lifehouse, Mater Hospital North Sydney, NSW; Clinical Professor, Medicine, Central Clinical School, University of Sydney, NSW., Scolyer RA; MD, Co-Medical Director, Melanoma Institute Australia, University of Sydney, Sydney, NSW; Clinical Professor, Discipline of Pathology, Faculty of Medicine and Health, University of Sydney, Sydney, NSW; Senior Staff Specialist in Anatomical Pathology, Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney, NSW., Long GV; BSc, PhD, MBBS, FRACP, Co-Medical Director, Melanoma Institute Australia, Vic; Chair of Melanoma Medical Oncology and Translational Research, Melanoma Institute Australia and Royal North Shore Hospital, University of Sydney, NSW., Spillane AJ; MD, FRACS, Professor of Surgical Oncology, Northern Clinical School, School of Medicine, Faculty of Medicine and Health, University of Sydney, NSW; Surgical Oncologist, Royal North Shore and Mater Hospitals, North Sydney, NSW., Henderson M; MBBS, BMedSc, MD, FRACS, Professor of Surgery, University of Melbourne, Vic; Surgeon, Melanoma and Skin Service, Breast Service and Sarcoma Service, Peter MacCallum Cancer Centre, Vic., Gyorki DE; MBBS, MD, FRACS, Consultant surgeon, Peter MacCallum Cancer Centre, Vic., Mar VJ; PhD, Director, Victorian Melanoma Service, Alfred Hospital, Melbourne, Vic; Adjunct Associate Professor, School of Public Health and Preventive Medicine, Monash University, Melbourne, Vic., Morton RL; MScMed, PhD (Clin Epi) (Hons), Director of Health Economics, NHMRC Clinical Trials Centre, Sydney Medical School, University of Sydney, NSW; Professor of Health Economics, Sydney Medical School, University of Sydney, NSW., Saw RP; FRACS, MS, MBBS, Associate Professor in Surgery, Central Clinical School, University of Sydney, NSW; Surgical Oncologist, Melanoma Institute Australia, NSW; General Surgeon, Royal Prince Alfred Hospital, NSW., Varey AH; BSc (Med), MBBS (Hons), FRACP, PhD, Medical Oncologist, Melanoma Institute Australia, Royal North Shore and Mater Hospitals, NSW; Associate Professor, Melanoma Medical Oncology, University of Sydney, NSW., Mann GJ; MBBS, PhD, FRACP, Director, John Curtin School of Medical Research, Australian National University, ACT; Principal Investigator, Melanoma Institute Australia, University of Sydney, NSW., Thompson JF; MD, Chairman, Australian Melanoma Clinical Practice Guidelines Working Party; Professor of Melanoma and Surgical Oncology, University of Sydney, Sydney, NSW; Surgeon, Royal Prince Alfred Hospital and Melanoma Institute Australia, Sydney, NSW. john.thompson@melanoma.org.au., Cust AE; MPH (Hons), PhD, Head of Cancer Epidemiology and Prevention Research Group, Sydney School of Public Health and Melanoma Institute Australia, University of Sydney, NSW; Professor of Cancer Epidemiology, Sydney Medical School, University of Sydney, NSW.

Publikováno v: Australian journal of general practice [Aust J Gen Pract] 2020 Jun; Vol. 49 (6), pp. 355-362.

Alternative splicing of TIA-1 in human colon cancer regulates VEGF isoform expression, angiogenesis, tumour growth and bevacizumab resistance.

Autor: Hamdollah Zadeh MA; Microvascular Research Laboratories, Veterinary Sciences Building, School of Physiology and Pharmacology, University of Bristol, Southwell Street, Bristol BS2 8EJ, UK., Amin EM; Centre for Research in Biomedicine, Faculty of Health and Life Sciences, University of the West of England, Bristol BS16 1QY, UK., Hoareau-Aveilla C; Microvascular Research Laboratories, Veterinary Sciences Building, School of Physiology and Pharmacology, University of Bristol, Southwell Street, Bristol BS2 8EJ, UK., Domingo E; Molecular and Population Genetics, Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford OX3 7BN, UK., Symonds KE; Microvascular Research Laboratories, Veterinary Sciences Building, School of Physiology and Pharmacology, University of Bristol, Southwell Street, Bristol BS2 8EJ, UK., Ye X; Microvascular Research Laboratories, Veterinary Sciences Building, School of Physiology and Pharmacology, University of Bristol, Southwell Street, Bristol BS2 8EJ, UK., Heesom KJ; Proteomics Facility, Faculty of Veterinary and Medical Sciences, University of Bristol, Bristol BS8 1TD, UK., Salmon A; Microvascular Research Laboratories, Veterinary Sciences Building, School of Physiology and Pharmacology, University of Bristol, Southwell Street, Bristol BS2 8EJ, UK., D'Silva O; Microvascular Research Laboratories, Veterinary Sciences Building, School of Physiology and Pharmacology, University of Bristol, Southwell Street, Bristol BS2 8EJ, UK., Betteridge KB; Microvascular Research Laboratories, Veterinary Sciences Building, School of Physiology and Pharmacology, University of Bristol, Southwell Street, Bristol BS2 8EJ, UK., Williams AC; School of Cellular and Molecular Medicine, School of Medical Sciences, University of Bristol, Bristol BS8 1TD, UK., Kerr DJ; Nuffield Dept Clinical and Laboratory Sciences, University of Oxford, UK., Salmon AH; Microvascular Research Laboratories, Veterinary Sciences Building, School of Physiology and Pharmacology, University of Bristol, Southwell Street, Bristol BS2 8EJ, UK., Oltean S; Microvascular Research Laboratories, Veterinary Sciences Building, School of Physiology and Pharmacology, University of Bristol, Southwell Street, Bristol BS2 8EJ, UK., Midgley RS; Molecular and Population Genetics, Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford OX3 7BN, UK., Ladomery MR; Centre for Research in Biomedicine, Faculty of Health and Life Sciences, University of the West of England, Bristol BS16 1QY, UK., Harper SJ; Microvascular Research Laboratories, Veterinary Sciences Building, School of Physiology and Pharmacology, University of Bristol, Southwell Street, Bristol BS2 8EJ, UK., Varey AH; Microvascular Research Laboratories, Veterinary Sciences Building, School of Physiology and Pharmacology, University of Bristol, Southwell Street, Bristol BS2 8EJ, UK., Bates DO; Microvascular Research Laboratories, Veterinary Sciences Building, School of Physiology and Pharmacology, University of Bristol, Southwell Street, Bristol BS2 8EJ, UK; Cancer Biology, Division of Cancer and Stem Cells, School of Medicine, University of Nottingham, Queen's Medical Centre, NG7 2UH, UK. Electronic address: David.Bates@nottingham.ac.uk.

Publikováno v: Molecular oncology [Mol Oncol] 2015 Jan; Vol. 9 (1), pp. 167-78. Date of Electronic Publication: 2014 Aug 20.

Association between VEGF splice isoforms and progression-free survival in metastatic colorectal cancer patients treated with bevacizumab.

Autor: Bates DO; Microvascular Research Laboratories, Department of Physiology and Pharmacology, University of Bristol, Bristol, United Kingdom. Dave.Bates@bristol.ac.uk, Catalano PJ, Symonds KE, Varey AH, Ramani P, O'Dwyer PJ, Giantonio BJ, Meropol NJ, Benson AB, Harper SJ

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2012 Nov 15; Vol. 18 (22), pp. 6384-91. Date of Electronic Publication: 2012 Oct 25.